Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
Supporting Evidence-based Responses to Emotional Needs in Emphysema
Families play an important role in the experiences of
patients with chronic illnesses, including chronic obstructive pulmonary
disease (COPD). This study aims to identify how an evidence-based coping skills
training program, where patients and a support person work together to manage
and overcome disease-related distress, can reduce depression and anxiety among
outpatients with COPD. The findings will provide a better understanding of how
social relationships impact patients' health and will help health systems
design and implement effective strategies for family-centered chronic illness
care, particularly for families experiencing health disparities.
Autism Spectrum Program of Excellence
The goal of the ASPE study is to investigate the genetic basis of autism spectrum disorder (ASD) and autism-related traits.Individuals 3 years old or older with a diagnosis (or suspected diagnosis) of autism spectrum disorder without intellectual disability may be eligible to participate. We are also recruiting individuals with a deletion in the NRXN1 gene (2p16.3 deletion) and their family members.Additionally, we are recruiting people who are not on the autism spectrum to act as our control (comparison) group.Visit www.aspe.med.upenn.edu or contact a member of the study team at aspe@pennmedicine.upenn.edu to learn how you can join the ASPE Study's growing community today!
TZIELD® (teplizumab-mzwv) in Patients with Stage 2 Type 1 Diabetes
Are you at risk for type 1 diabetes?Are you willing to receive a phone call every 6 months?For patients treated with TZIELD AND NOT treated with TZIELDYou may qualify to participate in an observational research studyAn observational study (you will not receive any experimental medication)Does not require on-site visitsParticipation will not change your treatment or medical care in any way Compensation for your time provided.Send us a message below or contact our study coordinator:Wendy Yang215-746-8136wendy.yang@pennmedicine.upenn.edu
IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT
Phase 1
The purpose of this study is to study a new radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body to see how it is taken up in the body and the brain using an imaging procedure called Positron Emission Tomography (PET/CT). Imaging PARP-1 activity in various cancers may help researchers to better understand it’s function and determine the best way to use imaging to help study new treatments that target the PARP-1 enzyme.
RevitaT2Di Pivotal Study (REVITALIZE 1)
The Revitalize-1 Study will look at a potential procedure called duodenal mucosal resurfacing (DMR). The DMR procedure acts on the first layer (mucosa) of the duodenum (the part of the small intestine located immediately after the stomach). By removing an excess layer, the treatment may improve blood sugar control. This treatment may eliminate or reduce the need for insulin injections in the future for the treatment of Type 2 Diabetes.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
